[HTML][HTML] Central serous chorioretinopathy: recent findings and new physiopathology hypothesis
Central serous chorioretinopathy (CSCR) is a major cause of vision threat among middle-
aged male individuals. Multimodal imaging led to the description of a wide range of CSCR …
aged male individuals. Multimodal imaging led to the description of a wide range of CSCR …
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
U Schmidt-Erfurth, V Chong, A Loewenstein… - British Journal of …, 2014 - bjo.bmj.com
Age-related macular degeneration (AMD) is still referred to as the leading cause of severe
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …
and irreversible visual loss world-wide. The disease has a profound effect on quality of life of …
Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management
CMG Cheung, TYY Lai, P Ruamviboonsuk, SJ Chen… - Ophthalmology, 2018 - Elsevier
Polypoidal choroidal vasculopathy (PCV) is an age-related macular degeneration (AMD)
subtype and is seen particularly in Asians. Previous studies have suggested disparity in …
subtype and is seen particularly in Asians. Previous studies have suggested disparity in …
Defining response to anti-VEGF therapies in neovascular AMD
WM Amoaku, U Chakravarthy, R Gale, M Gavin… - Eye, 2015 - nature.com
The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant
impact on the reduction of the visual loss due to neovascular age-related macular …
impact on the reduction of the visual loss due to neovascular age-related macular …
Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial
Importance Polypoidal choroidal vasculopathy (PCV) is a common subtype of exudative age-
related macular degeneration among Asian individuals. To our knowledge, there are no …
related macular degeneration among Asian individuals. To our knowledge, there are no …
Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial
Importance The 2-year efficacy and safety of combination therapy of ranibizumab
administered together with verteporfin photodynamic therapy (vPDT) compared with …
administered together with verteporfin photodynamic therapy (vPDT) compared with …
[HTML][HTML] Serous business: delineating the broad spectrum of diseases with subretinal fluid in the macula
EHC van Dijk, CJF Boon - Progress in retinal and eye research, 2021 - Elsevier
A wide range of ocular diseases can present with serous subretinal fluid in the macula and
therefore clinically mimic central serous chorioretinopathy (CSC). In this manuscript, we …
therefore clinically mimic central serous chorioretinopathy (CSC). In this manuscript, we …
Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration-the potential sources and molecular cues for their recruitment and …
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in
developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision …
developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision …
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
Y Ogura, GJ Jaffe, CMG Cheung, GT Kokame… - British Journal of …, 2022 - bjo.bmj.com
Purpose To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with
polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. Design HAWK …
polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. Design HAWK …
One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy
A Ito, M Maruyama-Inoue, Y Kitajima, S Ikeda… - Scientific Reports, 2022 - nature.com
To evaluate the 1-year visual outcomes and anatomic responses of Japanese patients who
received intravitreal brolucizumab (IVBr) injections for polypoidal choroidal vasculopathy …
received intravitreal brolucizumab (IVBr) injections for polypoidal choroidal vasculopathy …